CA2792413C - Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient - Google Patents
Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient Download PDFInfo
- Publication number
- CA2792413C CA2792413C CA2792413A CA2792413A CA2792413C CA 2792413 C CA2792413 C CA 2792413C CA 2792413 A CA2792413 A CA 2792413A CA 2792413 A CA2792413 A CA 2792413A CA 2792413 C CA2792413 C CA 2792413C
- Authority
- CA
- Canada
- Prior art keywords
- dlk1
- cancer
- fusion protein
- cell
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0023180 | 2010-03-16 | ||
KR1020100023180A KR100982170B1 (ko) | 2010-03-16 | 2010-03-16 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
PCT/KR2010/002277 WO2011115323A1 (ko) | 2010-03-16 | 2010-04-13 | 디엘케이원-에프씨 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2792413A1 CA2792413A1 (en) | 2011-09-22 |
CA2792413C true CA2792413C (en) | 2015-12-01 |
Family
ID=43010111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2792413A Expired - Fee Related CA2792413C (en) | 2010-03-16 | 2010-04-13 | Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient |
Country Status (11)
Country | Link |
---|---|
US (1) | US8785392B2 (ko) |
EP (1) | EP2548887B1 (ko) |
JP (1) | JP5367905B2 (ko) |
KR (1) | KR100982170B1 (ko) |
CN (1) | CN102341408B (ko) |
AU (1) | AU2010348423B2 (ko) |
BR (1) | BR112012023416A2 (ko) |
CA (1) | CA2792413C (ko) |
MX (1) | MX342222B (ko) |
RU (1) | RU2531756C2 (ko) |
WO (1) | WO2011115323A1 (ko) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100982170B1 (ko) | 2010-03-16 | 2010-09-15 | 한국생명공학연구원 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
WO2012138102A2 (ko) * | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물 |
WO2012138100A2 (ko) * | 2011-04-04 | 2012-10-11 | 한국생명공학연구원 | Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제 |
KR101461706B1 (ko) | 2011-04-04 | 2014-11-18 | 한국생명공학연구원 | Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제 |
CN102778566B (zh) * | 2011-05-07 | 2016-01-13 | 上海市肿瘤研究所 | Dlk1在肝癌诊断及预后判断中的应用 |
KR101995751B1 (ko) * | 2012-01-05 | 2019-07-03 | 주식회사 와이바이오로직스 | Dlk1 세포 외 수용성 도메인을 유효성분으로 포함하는 미오스타틴 저해제 |
WO2014129590A1 (ja) * | 2013-02-21 | 2014-08-28 | 国立大学法人九州大学 | Cyclin D1遺伝子発現抑制剤および抗腫瘍剤 |
CN105765063B (zh) | 2013-09-30 | 2021-05-07 | 中外制药株式会社 | 应用改变的辅助噬菌体制备抗原结合分子的方法 |
CN104711341B (zh) * | 2013-12-17 | 2019-10-22 | 上海市肿瘤研究所 | Dlk1基因在制备胃肠道间质瘤诊断试剂中的应用 |
WO2019050362A2 (ko) * | 2017-09-08 | 2019-03-14 | 주식회사 와이바이오로직스 | 인간 dlk1에 대한 항체 및 이의 용도 |
CN108130311B (zh) * | 2017-12-19 | 2020-12-08 | 柴怡 | 一种人原代结肠癌肝转移细胞株hcs1220 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
ES2151542T3 (es) * | 1992-12-11 | 2001-01-01 | Us Health | Gen del tipo delta expresado en tumores neuroendocrinos. |
EP0938332A4 (en) * | 1996-03-01 | 2003-05-28 | Imclone Systems Inc | USE OF DELTA-LIKE PROTEINS TO INHIBIT THE DIFFERENTIATION OF STEM CELLS |
US20020064855A1 (en) * | 1999-08-20 | 2002-05-30 | Ihor Lemischka | Genes that regulate hematopoietic blood forming stem cells and uses thereof |
JP2007531707A (ja) * | 2003-10-15 | 2007-11-08 | ピーディーエル バイオファーマ, インコーポレイテッド | IGの重鎖定常領域の位置250、314および/または428の変異誘発によるFc融合タンパク質血清半減期の改変 |
US8227578B2 (en) | 2006-11-10 | 2012-07-24 | Abe, Ikubo & Katayama | Anti-human dlk-1 antibody showing anti-tumor activity in vivo |
ES2527521T3 (es) * | 2008-03-17 | 2015-01-26 | Livtech Inc. | Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral |
KR100982170B1 (ko) | 2010-03-16 | 2010-09-15 | 한국생명공학연구원 | DLK1―Fc 융합 단백질을 유효성분으로 함유하는 암 전이 억제용 조성물 |
-
2010
- 2010-03-16 KR KR1020100023180A patent/KR100982170B1/ko active IP Right Grant
- 2010-04-13 US US13/142,818 patent/US8785392B2/en active Active
- 2010-04-13 EP EP10838389.4A patent/EP2548887B1/en not_active Not-in-force
- 2010-04-13 RU RU2012143943/10A patent/RU2531756C2/ru not_active IP Right Cessation
- 2010-04-13 CN CN201080013202.XA patent/CN102341408B/zh not_active Expired - Fee Related
- 2010-04-13 MX MX2012010560A patent/MX342222B/es active IP Right Grant
- 2010-04-13 BR BR112012023416A patent/BR112012023416A2/pt not_active Application Discontinuation
- 2010-04-13 CA CA2792413A patent/CA2792413C/en not_active Expired - Fee Related
- 2010-04-13 JP JP2012505813A patent/JP5367905B2/ja not_active Expired - Fee Related
- 2010-04-13 AU AU2010348423A patent/AU2010348423B2/en not_active Ceased
- 2010-04-13 WO PCT/KR2010/002277 patent/WO2011115323A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2548887B1 (en) | 2015-05-27 |
US8785392B2 (en) | 2014-07-22 |
WO2011115323A1 (ko) | 2011-09-22 |
MX2012010560A (es) | 2012-12-10 |
CN102341408B (zh) | 2014-09-10 |
JP5367905B2 (ja) | 2013-12-11 |
EP2548887A1 (en) | 2013-01-23 |
US20130202592A1 (en) | 2013-08-08 |
BR112012023416A2 (pt) | 2017-03-21 |
CA2792413A1 (en) | 2011-09-22 |
CN102341408A (zh) | 2012-02-01 |
KR100982170B1 (ko) | 2010-09-15 |
AU2010348423A1 (en) | 2012-10-25 |
RU2531756C2 (ru) | 2014-10-27 |
AU2010348423B2 (en) | 2014-04-10 |
JP2012513775A (ja) | 2012-06-21 |
MX342222B (es) | 2016-09-21 |
EP2548887A4 (en) | 2013-12-04 |
RU2012143943A (ru) | 2014-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2792413C (en) | Composition for the anti-cancer metastasis containing dlk1-fc fusion protein as an effective ingredient | |
Hand et al. | Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody | |
TW393489B (en) | Recombinant antibodies for human therapy | |
US7070959B1 (en) | Modified chimeric polypeptides with improved pharmacokinetic properties | |
JPH01502669A (ja) | 精製された血小板由来の成長因子及びその精製方法 | |
Evans et al. | Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cells | |
CN108135968A (zh) | 嵌合多肽组装体及其制备和使用方法 | |
CN101802002A (zh) | 结合人蛋白酪氨酸磷酸酶β(HPTPβ)的抗体及其用途 | |
CN110090295B (zh) | Ephrin-B1在制备治疗炎症性肠病的药物中的用途 | |
EA011859B1 (ru) | Соединения для адресной доставки препарата к ткани или органу-мишени | |
CN106188282B (zh) | 抗诺如病毒gi.1型鼠源单克隆抗体的制备和应用 | |
JPH07504802A (ja) | 遺伝子操作抗体 | |
MARESH et al. | Cloning and expression of the gene for the melanoma-associated ME20 antigen | |
CN102936283A (zh) | 抗人cd146的单克隆抗体,包含其的组合物,检测可溶性cd146的方法 | |
US7074411B1 (en) | α-β C4BP-type recombinant heteromultimeric proteins | |
CN102850456A (zh) | 一种血管内皮生长因子人源化单克隆抗体及其制备方法和用途 | |
CN101896502A (zh) | 抗人TNFα单抗、分子进化及其应用 | |
EP0269677A1 (en) | ASSAYS AND ANTIBODIES FOR N-$i(myc) PROTEINS | |
CN100398155C (zh) | 用于预防反刍动物捻转血矛线虫病的dna疫苗 | |
CN105461807B (zh) | 肿瘤相关基因tp53表位多肽单克隆抗体及其应用 | |
JP3385408B2 (ja) | 新規蛋白質とその抗体、並びにその新規蛋白質の製造方法 | |
CN106995801A (zh) | 抗树鼩cd4分子单克隆抗体及分泌该抗体的杂交瘤细胞株与应用 | |
CN102336834B (zh) | 全人TNFα-Fab抗体及其PEG化抗体 | |
CN103275212B (zh) | 抗人cd146的单克隆抗体,包含其的组合物,检测可溶性cd146的方法 | |
FI106129B (fi) | Menetelmät valmistaa muuntuneita CD44-pintaproteiineja ja näitä proteiineja vastaan vaikuttavia vasta-aineita |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190415 |